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Biomarker-guided initiation of antibiotic therapy has been studied in four conditions:
acute pancreatitis, lower respiratory tract infection (LRTI), meningitis, and sepsis in
the ICU. In pancreatitis with suspected infected necrosis, initiating antibiotics best
relies on fine-needle aspiration and demonstration of infected material. We suggest
that PCT be measured to help predict infection; however, available data are
insufficient to decide on initiating antibiotics based on PCT levels. In adult patients
suspected of community-acquired LRTI, we suggest withholding antibiotic therapy
when the serum PCT level is low (<0.25 ng/mL); in patients having nosocomial LRTI,
data are insufficient to recommend initiating therapy based on a single PCT level or
even repeated measurements. For children with suspected bacterial meningitis, we
recommend using a decision rule as an aid to therapeutic decisions, such as the
Bacterial Meningitis Score or the Meningitest(R); a single PCT level >/=0.5 ng/mL
also may be used, but false-negatives may occur. In adults with suspected bacterial
meningitis, we suggest integrating serum PCT measurements in a clinical decision
rule to help distinguish between viral and bacterial meningitis, using a 0.5 ng/mL
threshold. For ICU patients suspected of community-acquired infection, we do not
recommend using a threshold serum PCT value to help the decision to initiate
antibiotic therapy; data are insufficient to recommend using PCT serum kinetics for
the decision to initiate antibiotic therapy in patients suspected of ICU-acquired
infection. In children, CRP can probably be used to help discontinue therapy,
although the evidence is limited. In adults, antibiotic discontinuation can be based on
an algorithm using repeated PCT measurements. In non-immunocompromised out- or
in- patients treated for RTI, antibiotics can be discontinued if the PCT level at day 3 is
< 0.25 ng/mL or has decreased by >80-90%, whether or not microbiological
documentation has been obtained. For ICU patients who have nonbacteremic sepsis
from a known site of infection, antibiotics can be stopped if the PCT level at day 3 is
< 0.5 ng/mL or has decreased by >80% relative to the highest level recorded,
irrespective of the severity of the infectious episode; in bacteremic patients, a
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